6496.TWO Excelsior Biopharma
- Market cap
- TWD 1.07B
- P/E
- -
- P/B
- 1.56x
- ROE
- -32.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6496.TWO undervalued?
Graham numberThe Graham number of Excelsior Biopharma cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Excelsior Biopharma fundamental analysis
No fundamental analysis for Excelsior Biopharma yet.
Excelsior Biopharma stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Excelsior Biopharma
Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers general pharmaceuticals; orphan drugs; antidotes; rapid test kits and reagent; consumer products under the Repavar, Om3gafort, Oral7, and Excelsior Probiotics brand names; and over the counter drugs under the Norit, Puresenna, and Tazac brand names. The company also provides specialty medicine and public health products. In addition, it is involved in importin…
Full company profileExcelsior Biopharma financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Excelsior Biopharma annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 1.72B | 1.69B | 1.54B | 1.44B | 1.34B | 672M | 772M | 862M | 898M | 901M |
| Gross Profit | 668M | 586M | 354M | 310M | 293M | 287M | 307M | 382M | 360M | 343M |
| Operating Income | 326M | 282M | 84.8M | 46.8M | -1.02M | -25.3M | -74.6M | -78.7M | -174M | -224M |
| EBITDA | 363M | 312M | 122M | 74.1M | 27.6M | 745K | -28.4M | -8.41M | -92.9M | -138M |
| Net Income | 280M | 222M | 71.0M | 35.3M | -15.6M | -33.8M | -91.0M | -98.7M | -183M | -224M |
| EPS | 5.99 | 4.75 | 1.52 | 0.72 | -0.34 | -0.71 | -1.90 | -2.11 | -3.93 | -4.82 |
| Balance Sheet | ||||||||||
| Total Assets | 1.68B | 1.64B | 1.50B | 1.90B | 1.84B | 1.71B | 1.58B | 1.58B | 1.48B | 1.42B |
| Total Liabilities | 339M | 271M | 244M | 617M | 609M | 508M | 473M | 587M | 680M | 729M |
| Shareholders' Equity | 1.34B | 1.37B | 1.25B | 1.28B | 1.23B | 1.21B | 1.10B | 991M | 804M | 689M |
| Cash & Short-term Investments | 883M | 751M | 349M | 1.15B | 1.10B | 1.11B | 590M | 240M | 185M | 141M |
| Total Debt | - | - | - | 395M | 397M | 376M | 377M | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 349M | 127M | -170M | 521M | 55.8M | 5.49M | -135M | -99.8M | -139M | -120M |
| Capital Expenditure | 18.1M | 9.54M | 20.4M | 11.6M | 2.88M | 7.78M | 35.7M | 257M | 36.9M | 9.55M |
| Free Cash Flow | 331M | 117M | -190M | 509M | 52.9M | -2.30M | -170M | -357M | -176M | -130M |
| Ratios | ||||||||||
| ROE | 20.9% | 16.2% | 5.7% | 2.8% | -1.3% | -2.8% | -8.2% | -10.0% | -22.8% | -32.6% |
| ROA | 16.7% | 13.5% | 4.7% | 1.9% | -0.9% | -2.0% | -5.8% | -6.3% | -12.3% | -15.8% |
| Net Profit Margin | 16.3% | 13.1% | 4.6% | 2.4% | -1.2% | -5.0% | -11.8% | -11.5% | -20.4% | -24.9% |
| Debt to Equity | - | - | - | 0.31x | 0.32x | 0.31x | 0.34x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Excelsior Biopharma dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jul 13, 2021
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | TWD 46.7M | 1.00 | - |
| 2020 | TWD 46.7M | 0.95 | 132.2% |
| 2019 | TWD 187M | 4.00 | 262.9% |
| 2018 | TWD 187M | 4.00 | 84.2% |
| 2017 | TWD 187M | 4.00 | 66.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Excelsior Biopharma
- Insiders 64.84%
- Institutions 0.00%
- Public & others 35.16%
- Shares outstanding 46.5M
- Free float 15.3M
Excelsior Biopharma company profile
- Company name
- Excelsior Biopharma
- Ticker
- 6496.TWO
- ISIN
- TW0006496003
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- No. 508, Zhongxiao E. Rd., Taipei, Taiwan, 11561
- Phone
- 886 2 2655 7568
- Website
- excelsiorgroup.com.tw
About Excelsior Biopharma
Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers general pharmaceuticals; orphan drugs; antidotes; rapid test kits and reagent; consumer products under the Repavar, Om3gafort, Oral7, and Excelsior Probiotics brand names; and over the counter drugs under the Norit, Puresenna, and Tazac brand names. The company also provides specialty medicine and public health products. In addition, it is involved in importing and exporting of active pharmaceutical ingredients, food, and cosmeceuticals; development of cosmetics; research, importing and exporting of technologies; and pharmaceutical technologies transfer. The company was formerly known as Excelsior Enterprise Co., Ltd. and changed its name to Excelsior Biopharma Inc. in June 2003. Excelsior Biopharma Inc. was founded in 1986 and is headquartered in Taipei, Taiwan.
Excelsior Biopharma management
6- Mr. Joseph ChenFounder, Chairman, President & GM
- Ms. Chia-Ling ChenRepresentative Director, New Business Development Manager & Associate Manger to the President Office
- Mr. Po-Tang ChengSenior Director General of Taiwan Business Division
- Ms. Ya-Wen HuangDirector General of Consumer Product Business Division
- Ms. Pi-Ching WuDirector General of Specialty Medicine Business Division
- Mr. Ming-Tse ChenFinancial Manager & Chief Accountant